Pulmonary pleomorphic carcinoma with few PD‐1‐positive immune cells and regulatory T cells that showed a complete response to nivolumab

Pulmonary pleomorphic carcinoma has been shown to respond remarkably to PD‐1 inhibitors; however, the biomarkers for this therapy have not been fully proven. We report a case of pulmonary pleomorphic carcinoma with overexpressed PD‐L1, in which a complete response to nivolumab was sustained for >...

Descripción completa

Detalles Bibliográficos
Autores principales: Okamura, Kazuaki, Fukuda, Yuichi, Soda, Hiroshi, Ogawara, Daiki, Iwasaki, Keisuke, Fuchi, Shinichiro, Suyama, Takayuki, Yoshida, Masataka, Harada, Tatsuhiko, Fukuda, Minoru, Mukae, Hiroshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2017
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5754285/
https://www.ncbi.nlm.nih.gov/pubmed/29131510
http://dx.doi.org/10.1111/1759-7714.12557
Descripción
Sumario:Pulmonary pleomorphic carcinoma has been shown to respond remarkably to PD‐1 inhibitors; however, the biomarkers for this therapy have not been fully proven. We report a case of pulmonary pleomorphic carcinoma with overexpressed PD‐L1, in which a complete response to nivolumab was sustained for >14 months. Immunohistochemical analysis revealed few PD‐1(+) immune cells and regulatory T cells in the tumor, in addition to predominant infiltration of CD8(+) cells and macrophages. Our findings suggest that the presence of a small number of PD‐1(+) immune cells and regulatory T cells should be investigated as candidate therapeutic biomarkers.

Ejemplares similares